%0 Journal Article %A Kathy Leung %A Marcus HM Shum %A Gabriel M Leung %A Tommy TY Lam %A Joseph T Wu %T Early empirical assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020 %D 2020 %R 10.1101/2020.12.20.20248581 %J medRxiv %P 2020.12.20.20248581 %X Two new SARS-CoV-2 lineages with the N501Y mutation in the receptor binding domain of the spike protein have rapidly become prevalent in the UK. We estimated that the earlier 501Y lineage without amino acid deletion Δ69/Δ70 circulating mainly between early September to mid-November was 10% (6-13%) more transmissible than the 501N lineage, and the currently dominant 501Y lineage with amino acid deletion Δ69/Δ70 circulating since late September was 75% (70-80%) more transmissible than the 501N lineage.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by a commissioned grant from the Health and Medical Research Fund and General Research Fund (grant no.: 17110020) and a special grant of the InnoHK programme from the Government of the Hong Kong Special Administrative Region, and the National Natural Science Foundation of China (NSFC) Excellent Young Scientists Fund (Hong Kong and Macau) (grant no.: 31922087). The funding bodies had no role in study design, data collection and analysis, preparation of the manuscript, or the decision to publish. All authors have seen and approved the manuscript. All authors have contributed significantly to the work. All authors report no conflicts of interest. The manuscript and the data contained within have not been published and are not being considered for publication elsewhere.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research is based on SARS-CoV-2 sequences and COVID-19 data that are publicly available. Ethical approval is waived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe collated all data from publicly available data sources. All data included in the analyses are available in the main text or the supplementary materials. %U https://www.medrxiv.org/content/medrxiv/early/2020/12/22/2020.12.20.20248581.full.pdf